How should I diagnose and manage a patient with suspected porphyria presenting with abdominal pain, neurological symptoms, dark urine, and photosensitivity?

Diagnosis and Management of Suspected Porphyria

For any patient—especially women aged 15-50 years—presenting with unexplained recurrent severe abdominal pain, neurological symptoms, dark urine, and/or photosensitivity, immediately obtain a random urine sample for quantitative δ-aminolevulinic acid (ALA), porphobilinogen (PBG), and creatinine measurement to diagnose acute hepatic porphyria (AHP). 1

Diagnostic Approach

Initial Biochemical Testing

• Collect a random urine sample during symptoms for quantitative measurement of ALA, PBG, porphyrins, and creatinine—a 24-hour collection is NOT recommended 1
• During acute attacks, both ALA and PBG are elevated at least 5-fold above the upper limit of normal in all AHP types except ALAD porphyria (where only ALA is elevated) 1
• Normalize ALA and PBG values to creatinine to account for urinary concentration differences 1
• If urine creatinine is <2 mmol/L, request a repeat sample as the specimen is too dilute 2

Critical pitfall: Do NOT use urine porphyrins alone as a screening test—mild elevations in urinary porphyrins (secondary porphyrinurias) occur in many common conditions and lead to erroneous overdiagnosis of AHP 1. The hallmark diagnostic finding is significantly elevated ALA and PBG, not porphyrins.

Timing Considerations

• Best diagnostic yield: Test during an acute attack before hemin treatment 1
• In acute intermittent porphyria (AIP), ALA and PBG can remain elevated for months to years after an attack 1
• In hereditary coproporphyria (HCP) and variegate porphyria (VP), levels may fall quickly post-attack 1
• In patients with recurrent attacks, ALA and PBG are typically elevated even at baseline between attacks 1
• If symptoms are frequent but ALA/PBG are normal, AHP is effectively ruled out as the cause 1

Confirmatory Testing

Once biochemical testing confirms elevated ALA and PBG:

• Genetic testing should identify the specific AHP subtype by sequencing ALAD, HMBS, CPOX, and PPOX genes (corresponding to ALAD porphyria, AIP, HCP, and VP respectively) 1
• Whole-gene sequencing identifies 95-99% of cases 1
• Screen first-degree family members with genetic testing once the familial pathogenic variant is identified 1

Distinguishing Cutaneous Porphyrias

For patients presenting primarily with photosensitivity:

• Obtain EDTA blood for plasma porphyrin fluorescence emission spectroscopy and random urine for total urinary porphyrins 2
• Whole blood porphyrin analysis is essential to identify erythropoietic protoporphyria 2
• Fecal porphyrins are only needed if first-line tests are positive or symptoms persist 2

Acute Attack Management

Immediate Interventions

Begin intravenous hemin (3-4 mg/kg body weight once daily, typically for 4 days) as soon as possible—even before biochemical results return if AHP is confirmed and the clinical presentation is consistent with an acute attack. 1

The management algorithm proceeds as follows:

1. Collect random urine for ALA, PBG, and creatinine BEFORE starting hemin 1
2. Stop all porphyrinogenic medications immediately (consult www.porphyria.org/patient-resources/drug-safety-database-for-ahp/ or www.drugs-porphyria.org) 1
3. Administer hemin via peripherally inserted central catheter or central port to avoid thrombophlebitis—use heme bound to human serum albumin when available for better vein tolerance 1
4. Provide intravenous carbohydrate loading (approximately 300 g/day in adults) during early attack stages, as fasting induces ALAS1 expression 1

Symptomatic Management

• Aggressive pain control with analgesics (avoid contraindicated medications) 1
• Antiemetics for nausea and vomiting 1
• Monitor and correct electrolytes: hyponatremia and hypomagnesemia are common due to hypovolemia and SIADH—correct sodium slowly if present 1
• Manage hypertension and tachycardia as needed 1

Seizure Management Caveat

If seizures occur, avoid barbiturates, hydantoins, carbamazepine, and valproic acid—these are contraindicated in AHP. Safe options include:

• Magnesium sulfate
• Benzodiazepines
• Levetiracetam 1

Expected Response

• Hemin rapidly down-regulates hepatic ALAS1 expression, stopping ALA and PBG overproduction 1
• Symptom relief typically requires 48-72 hours as excess ALA and PBG are eliminated 1
• Recovery from neurologic symptoms varies significantly 1
• Timely hemin initiation decreases risk of long-term neurologic complications 1

Long-Term Management

Trigger Avoidance

Counsel all patients to strictly avoid precipitating factors 1:

• Porphyrinogenic medications (cytochrome P450 inducers)
• Alcohol and tobacco
• Caloric deprivation/fasting
• Physical or psychological stress
• Acute illness or infection
• Sex hormones (particularly progesterone)

Prophylactic Therapy

For patients with recurrent attacks (≥4 per year), initiate prophylactic therapy with either intravenous hemin or subcutaneous givosiran. 1

• Women with menstrual cycle-associated attacks may benefit from hormonal suppression therapy (GnRH agonists), though success is limited 1
• Off-label prophylactic intravenous hemin infusion is commonly used 1
• Givosiran represents a newer targeted prophylactic option 1

Surveillance

Patients with AHP face long-term risks requiring monitoring:

• Systemic arterial hypertension
• Chronic renal disease
• Chronic liver disease
• Hepatocellular carcinoma 1

Clinical Recognition Pearls

The diagnosis of AHP is frequently delayed by an average of 15 years from symptom onset in the United States and Europe 1. Maintain high clinical suspicion for:

• Recurrent severe abdominal pain without peritoneal signs or abnormalities on cross-sectional imaging 1
• Women of childbearing age (acute attacks occur mainly in this demographic) 1
• Dark urine during symptomatic periods
• Neurological symptoms including peripheral neuropathy, muscle weakness, or psychiatric manifestations
• Autonomic dysfunction (tachycardia, hypertension)

The combination of these features, particularly in a young woman with unexplained recurrent abdominal pain, should immediately trigger biochemical testing for AHP 1.